Curis Past Earnings Performance
Past criteria checks 0/6
Curis's earnings have been declining at an average annual rate of -11.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 0.8% per year.
Key information
-11.3%
Earnings growth rate
16.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -0.8% |
| Return on equity | n/a |
| Net Margin | -443.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Nov 14
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Aug 07Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
Aug 05Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 03Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry
Dec 26We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate
Nov 03We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
Aug 05Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Apr 19Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?
Jan 02Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Sep 16Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study
Aug 18Curis: Asymmetric Risk And Reward
Jul 17Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation
Mar 28Checking In On Curis
Dec 15Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth
Dec 04We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth
Aug 29Curis Inc.: Revisiting CA-4948 After Q2 Update
Aug 25Revenue & Expenses Breakdown
How Curis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -45 | 18 | 0 |
| 30 Jun 24 | 10 | -48 | 19 | 0 |
| 31 Mar 24 | 10 | -48 | 19 | 0 |
| 31 Dec 23 | 10 | -47 | 19 | 0 |
| 30 Sep 23 | 10 | -47 | 18 | 27 |
| 30 Jun 23 | 10 | -48 | 18 | 0 |
| 31 Mar 23 | 10 | -52 | 19 | 0 |
| 31 Dec 22 | 10 | -57 | 20 | 0 |
| 30 Sep 22 | 10 | -59 | 20 | 0 |
| 30 Jun 22 | 11 | -57 | 20 | 0 |
| 31 Mar 22 | 11 | -52 | 19 | 0 |
| 31 Dec 21 | 11 | -45 | 17 | 0 |
| 30 Sep 21 | 11 | -39 | 16 | 0 |
| 30 Jun 21 | 10 | -34 | 14 | 0 |
| 31 Mar 21 | 10 | -30 | 13 | 0 |
| 31 Dec 20 | 11 | -30 | 12 | 0 |
| 30 Sep 20 | 11 | -31 | 12 | 0 |
| 30 Jun 20 | 11 | -31 | 12 | 0 |
| 31 Mar 20 | 11 | -32 | 12 | 0 |
| 31 Dec 19 | 10 | -32 | 12 | 0 |
| 30 Sep 19 | 9 | -29 | 12 | 0 |
| 30 Jun 19 | 9 | -30 | 13 | 0 |
| 31 Mar 19 | 10 | -32 | 14 | 0 |
| 31 Dec 18 | 10 | -33 | 15 | 0 |
| 30 Sep 18 | 11 | -35 | 15 | 0 |
| 30 Jun 18 | 11 | -43 | 14 | 0 |
| 31 Mar 18 | 10 | -48 | 15 | 0 |
| 31 Dec 17 | 10 | -53 | 14 | 0 |
| 30 Sep 17 | 9 | -57 | 15 | 0 |
| 30 Jun 17 | 8 | -70 | 16 | 0 |
| 31 Mar 17 | 8 | -67 | 16 | 0 |
| 31 Dec 16 | 8 | -60 | 16 | 0 |
| 30 Sep 16 | 7 | -63 | 15 | 0 |
| 30 Jun 16 | 8 | -40 | 13 | 0 |
| 31 Mar 16 | 8 | -37 | 13 | 0 |
| 31 Dec 15 | 8 | -59 | 13 | 0 |
| 30 Sep 15 | 8 | -51 | 13 | 0 |
| 30 Jun 15 | 7 | -51 | 13 | 0 |
| 31 Mar 15 | 10 | -45 | 12 | 0 |
| 31 Dec 14 | 10 | -19 | 12 | 0 |
| 30 Sep 14 | 9 | -17 | 11 | 0 |
| 30 Jun 14 | 15 | -14 | 12 | 0 |
| 31 Mar 14 | 15 | -13 | 12 | 0 |
| 31 Dec 13 | 15 | -12 | 11 | 0 |
Quality Earnings: CRIS is currently unprofitable.
Growing Profit Margin: CRIS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRIS is unprofitable, and losses have increased over the past 5 years at a rate of 11.3% per year.
Accelerating Growth: Unable to compare CRIS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRIS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CRIS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.